Combination therapy: The future of management for idiopathic pulmonary fibrosis?

The Lancet Respiratory Medicine

Volumn 2, Issue 11, 2014, Pages 933-942

  Wuyts, Wim A ^a   Antoniou, Katerina M ^b   Borensztajn, Keren ^c,d   Costabel, Ulrich ^e   Cottin, Vincent ^f   Crestani, Bruno ^c,d   Grutters, Jan C ^g   Maher, Toby M ^h   Poletti, Venerino ⁱ   Richeldi, Luca ^j   Vancheri, Carlo ^k   Wells, Athol U ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF CRETE   (Greece)

^c Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^d BICHAT HOSPITAL   (France)

^e RUHRLANDKLINIK   (Germany)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ MORGAGNI PIERANTONI HOSPITAL   (Italy)

^j University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^k UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; BUDESONIDE PLUS FORMOTEROL; CARLUMAB; CETUXIMAB; CISPLATIN; CORTICOSTEROID; ETANERCEPT; FG 3019; FRESOLIMUMAB; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; LEBRIKIZUMAB; MACITENTAN; NAVELBINE; NINTEDANIB; OMIPALISIB; PIRFENIDONE; PLATINUM COMPLEX; PREDNISOLONE; RAPAMYCIN; RIOCIGUAT; RITUXIMAB; SIMTUZUMAB; TANZISERTIB; TRALOKINUMAB; UMECLIDINIUM PLUS VILANTEROL; UNINDEXED DRUG; VISMODEGIB;

ANTIBIOTIC THERAPY; ASTHMA; BACTERIAL COLONIZATION; CANCER RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FRACTURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL ADMISSION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG CANCER; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; NOTE; PATHOGENESIS; PERSONALIZED MEDICINE; PNEUMONIA; PULMONARY HYPERTENSION; STUDY DESIGN; TRANSBRONCHIAL BIOPSY; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; INDIVIDUALIZED MEDICINE; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84918842765     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70232-2     Document Type: Note

References (66)

1. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathological subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199-203.
2. King TE, Pardo A, Selman M Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
3. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. for the CAPACITY Study Group.
4. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
5. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242. for the IFIGENIA Study Group.
6. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
7. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082. for the INPULSIS Trial Investigators.
8. Loomis-King H, Flaherty KR, Moore BB Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013, 13:377-385.
9. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188:733-748. for the ATS/ERS Committee on Idiopathic Interstitial Pneumonias.
10. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95. for the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).
11. Müller-Quernheim J, Wells A Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med 2012, 186:5-7.
12. Fernandez IE, Eickelberg O New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012, 380:680-688.
13. Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013, 41:1207-1218.
14. Richeldi L, Collard HR, du Bois RM, et al. Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. Eur Respir J 2013, 42:230-238.
15. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
16. Selman M, King TE, Pardo A Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001, 134:136-151.
17. Chaudhary NI, Schnapp A, Park JE Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006, 173:769-776.
18. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610. for the Imatinib-IPF Study Investigators.
19. Dillingh MR, van den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013, 26:672-676.
20. King TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:92-99.
21. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013, 42:1622-1632. for the MUSIC Study Group.
22. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649. for the ARTEMIS-IPF Investigators.
23. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948-955.
24. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011, 20:85-97.
25. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014, 31:375-391.
26. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004, 24:57-65.
27. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 2014, 58:13-19.
28. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
29. Beyer C, Distler JH Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta 2013, 1832:897-904.
30. Bonner JC Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273.
31. Calandrella N, Risuleo G, Scarsella G, et al. Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res 2007, 26:405-409.
32. Keane MP Angiogenesis and pulmonary fibrosis: feast or famine?. Am J Respir Crit Care Med 2004, 170:207-209.
33. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.
34. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014, 43:1430-1438.
35. Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 2004, 30:339-349.
36. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
37. Lipson KE, Wong C, Teng Y, Spong S CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012, 5:S24.
38. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin α(v)β6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008, 177:56-65.
39. Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin α(v)β6, an activator of latent transforming growth factor-β, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008, 177:82-90.
40. Hecker L, Cheng J, Thannickal VJ Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci 2012, 69:2365-2371.
41. Johnson DH, Schiller JH, Bunn PA Recent clinical advances in lung cancer management. J Clin Oncol 2014, 32:973-982.
42. Lwin Z, Riess JW, Gandara D The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis 2013, 5:S556-S564.
43. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global initiative for Chronic Obstructive Lung Disease (GOLD 2014), (accessed Sept 23, 2014). http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf.
44. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1:51-60.
45. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention, (accessed Sept 23, 2014). http://www.ginasthma.org/.
46. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014, 371:1189-1197. for the SIRIUS Investigators.
47. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340.
48. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
49. GSK announces first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study GSK, (accessed Sept 24, 2014). http://www.gsk.com/en-gb/media/press-releases/2014/gsk-announces-first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study/.
50. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014, 371:1198-1207. for the MENSA Investigators.
51. Reddy AP, Gupta MR Management of asthma: the current US and European guidelines. Adv Exp Med Biol 2014, 795:81-103.
52. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62:D60-D72.
53. Ghofrani A, Humbert M The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014, (in press).
54. Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014, 43:1691-1697.
55. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. for the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.
56. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013, 42:750-757.
57. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010, 181:832-837.
58. Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014, 9:e86716.
59. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014, published online Sept 3. 10.1164/rccm.201403-0541OC.
60. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomized controlled trial. Thorax 2013, 68:155-162.
61. Chilosi M, Carloni A, Rossi A, Poletti V Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 2013, 162:156-173.
62. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008, 102:1392-1398.
63. Kallenberg CG Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol 2014, 10:484-493.
64. Greenhalgh T, Howick J, Maskrey N Evidence based medicine: a movement in crisis?. BMJ 2014, 348:g3725. for the Evidence Based Medicine Renaissance Group.
65. Corte TJ, Wort SJ, Gatzoulis MA, MacDonald P, Hansell DM, Wells AU Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009, 64:883-888.
66. Cottin V, Wells AU Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category. Eur Respir J 2013, 42:576-579.